Israeli drug development company BioLineRX has announced that it will receive an $8 million investment from OrbiMed Israel Partners LP. BioLineRX says that it will use the funds to continue the development of its clinical and pre-clinical state therapeutic assets.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments